[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Zheng Liu\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":72},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":4},"100603678","early-phase-1-evidence-based-evaluation-of-classic-herb-pair-chuanxiong-rhizoma-and-salviae-miltiorrhizae-for-preventing-recurrence-of-diabetic-lower-extremity-arterial-disease-100603678",false,"NCT07139639","Evidence-Based Evaluation of Classic Herb Pair (Chuanxiong Rhizoma and Salviae Miltiorrhizae) for Preventing Recurrence of Diabetic Lower Extremity Arterial Disease","Evidence-Based Evaluation and New Drug Development of Classic Herb Pair (Chuanxiong Rhizoma and Salviae Miltiorrhizae) for Preventing Recurrence of Diabetic Lower Extremity Arterial Disease","Inclusion Criteria:\n\n1. Age: 18 to 80 years old (inclusive)\n2. Diagnosis: Confirmed type 1 or type 2 diabetes mellitus\n3. Meeting diagnostic criteria for diabetic lower extremity arterial disease (DLEAD)\n4. TCM Syndrome: Qualified for Qi Stagnation and Blood Stasis syndrome pattern\n5. Glycemic Control:\n\n   * HbA1c ≤9% or Fasting plasma glucose ≤10 mmol\u002FL\n6. Ulcer History:\n\n   * Documented history of diabetic lower extremity arterial disease (DLEAD)-related ulcers, with confirmed healing (wound re-epithelialization without signs of redness, purulent discharge, or infection) 2-8 weeks prior to enrollment.\n7. Consent: Voluntarily signed informed consent form\n\nExclusion Criteria:\n\n* (1) Ulcer Etiology Exclusion:\n* Pure pressure ulcers\n* Pure neuropathic ulcers\n* Immune-mediated ulcers (e.g., vasculitic ulcers caused by lupus, Behcet's disease, rheumatoid arthritis) (2) Recent Cardiovascular Events:\n* Acute coronary syndrome within 3 months\n* Hemorrhagic stroke within 3 months (3) Organ Dysfunction:\n* Severe hepatic impairment (AST or ALT \\>1.5×ULN)\n* Chronic kidney disease stage 4-5 (eGFR \\\u003C30 mL\u002Fmin\u002F1.73m²) (4) Recent Major Bleeding:\n* Gastrointestinal hemorrhage within 1 month (5) Concurrent TCM Therapy:\n* Use of blood-activating\u002Fstasis-resolving TCM preparations for DLEAD within 1 week (6) Herbal Contraindication:\n* Concurrent or planned use of \\*Veratrum\\*-containing preparations (7) Malignancy:\n* Active cancer progression (8) Reproductive Status:\n* Pregnant or lactating women (9) Allergy History:\n* Known hypersensitivity to \\*Ligusticum chuanxiong\\* or \\*Salvia miltiorrhiza\\* (10) Cognitive\u002FLanguage Barriers:\n* Psychiatric disorders\n* Intellectual\u002Flanguage impairment affecting scale completion\n* Unwillingness to cooperate (11) Life Expectancy:\n* \\\u003C1 year (12) Clinical Trial Participation:\n* Enrollment in other drug trials within 1 month (13) Investigator's Discretion:\n* Other conditions deemed unsuitable for participation","ALL","18 Years","80 Years",{"count":20,"type":21},350,"ESTIMATED","INTERVENTIONAL",[24],"EARLY_PHASE1","Taking the approach of promoting qi circulation and activating blood as the entry point, this study targets lower extremity arterial disease（LEAD） patients with TCM syndrome pattern of blood stasis due to qi stagnation. Using Guanxinning Tablets (a herbal formula with qi-moving and blood-activating properties) as the investigational medication, we will conduct a multicenter, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of the classic herb pair (Chuanxiong Rhizoma-Salviae Miltiorrhizae) in preventing LEAD ulcer recurrence. This research aims to accumulate evidence-based medical data supporting new drug development.",[27],"Diabetic Lower Extremity Arterial Disease",[29,30,31,32,33,34,35],"Recurrence of ulcer","Diabetic Lower extremity arterial disease","Interventional Study","Prevention","Guanxinning Tablets","Salviae Miltiorrhizae","Chuanxiong Rhizoma","NOT_YET_RECRUITING","2025-08-18",{"date":39,"type":40},"2025-08-24","ACTUAL",{"date":42,"type":21},"2025-11-01",{"date":44,"type":21},"2028-12-01",{"name":46,"class":47},"Zheng Liu","OTHER",{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":5},"100551617","efficacy-and-safety-of-arbidol-in-the-treatment-of-allergic-rhinitis-100551617","NCT06462417","Efficacy and Safety of Arbidol in the Treatment of Allergic Rhinitis","Study on the Efficacy and Safety of Oral Administration of Arbidol in the Treatment of Allergic Rhinitis Patients","Inclusion Criteria:\n\n* 1\\. Patients with allergic rhinitis (in line with the diagnostic criteria of the \"Guidelines for the Diagnosis and Treatment of Allergic Rhinitis (2015, Tianjin)\" formulated by the Rhinology Group of the Otolaryngology-Head and Neck Surgery Branch of the Chinese Medical Association).\n* 2\\. At least 2 nasal symptoms are moderate or above (referring to sneezing, runny nose, nasal itching, nasal congestion with at least 2 symptoms ≥2 points).\n* 3\\. Female subjects are not pregnant or lactating and have no pregnancy and lactation plans during the trial medication period.\n* 4\\. The subject has not participated in other clinical trials in the previous three months and agrees not to participate in other clinical trials before reaching the endpoint of this trial.\n* 5\\. The subject\u002Flegally authorized representative understands the purpose and procedures of the trial and voluntarily signs the informed consent form, voluntarily participates in the study and complies with the study regulations, understands and complies with the medication dosage and follow-up plan, and correctly records the scale score, the number of medications, concomitant medication and adverse event records.\n\nExclusion Criteria:\n\n* 1\\. Who are allergic to Arbidol.\n* 2\\. Patients with abnormal liver and kidney function (ALT and AST exceed the maximum limit of normal value by 1.5 times, and Cr exceeds the upper limit of normal value).\n* 3\\. Patients with abnormal ECG parameters and clinically significant (PR\\>220ms, QRS\\>120ms, QTc\\>450ms) and bradycardia.\n* 4\\. Patients with severe asthma or acute asthma exacerbations.\n* 5\\. Patients with structural heart disease, severe hypertension (blood pressure greater than 180\u002F110mmHg), diabetes, hyperthyroidism, malignant tumors, immunocompromise, and mental illness. Patients with structural heart disease, severe hypertension (blood pressure greater than 180\u002F110mmHg), diabetes, hyperthyroidism, malignant tumors, immunocompromise, and mental illness.\n* 6\\. Patients with nasal polyps, severe deviated nasal septum, sinusitis, and hypertrophic rhinitis.\n* 7\\. Who have participated in other clinical studies within 3 months.\n* 8\\. Women are pregnant or lactating, in childbearing age with positive blood pregnancy test, or have pregnancy and lactation plans during the trial medication.\n* 9\\. Drug abuse and alcoholism.\n* 10\\. Who have received allergen-specific immunotherapy within 3 years.\n* 11\\. Positive infectious disease screening (hepatitis B surface antigen, hepatitis C antibody, AIDS antibody and treponema pallidum antibody).\n* 12\\. Who should not be included if there are other reasons in the opinion of the investigator.","65 Years",{"count":57,"type":21},15,[59],"NA","The most important treatment for AR is topical nasal medications (including nasal corticosteroids, nasal antihistamines, nasal decongestants, and nasal saline irrigation etc.), which are still limited. Arbidol may inhibit molecular targets involved in the pathogenesis of AR. This study intends to explore the effect of Arbidol in the treatment of allergic rhinitis and evaluate its efficacy and safety.",[62],"Allergic Rhinitis","RECRUITING","2025-05-03",{"date":66,"type":40},"2025-05-07",{"date":68,"type":40},"2024-07-11",{"date":70,"type":21},"2025-06-30",{"name":46,"class":47},""]